Synonyms: Compound A [WO2022174269A1] | KT474
Compound class:
Synthetic organic
Comment: KT-474 is a PROTAC degrader of interleukin 1 receptor associated kinase 4 (IRAK4). It is in Kymera Therapeutics' pipeline and is initially being developed for potential to treat the autoimmune conditions atopic dermatitis and hidradenitis suppurativa [2]. A thalidomide analogue moiety is employed to direct the bound IRAK4 to the ubiquitin-proteasome pathway via the thalidomide-cereblon interaction.
|
|
References |
1. Mainolfi N, Ji N, Kluge AF, Weiss MM, Zhang Y, Zheng X. (2020)
Irak degraders and uses thereof. Patent number: WO2020113233A1. Assignee: Kymera Therapeutics, Inc.. Priority date: 02/12/2019. Publication date: 04/06/2020. |
2. Rong H, Enerson B. (2022)
Irak4 degraders and uses thereof. Patent number: WO2022174269A1. Assignee: Kymera Therapeutics, Inc.. Priority date: 15/02/2022. Publication date: 19/08/2022. |